Filing Flows

Filing Flows › Health Care › Biofrontera (BFRI)

Biofrontera (BFRI) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Biofrontera (BFRI) Q2 2026 earnings results →

Q2 2026 Revenue up 33% year over year to $12.0M · 5¢ of every $1 of revenue lost · operating margin -4.4%

Biofrontera made $12.0M in Q2 2026 (+33% Y/Y). Operating margin -4.4%, net loss $604K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Revenue$12.0M
Year over year+33%
Operating margin-4.4%
Net earnings−$604K
Operating cash flow−$1.7M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $12.0M in Q2 2026, up 33% year over year and up 19% from the previous quarter.

Operating costs exceeded revenue by $524K, an operating margin of -4.4%. Total costs fell 11% while revenue rose 33%. The quarter ended with a net loss of $604K, narrower than the previous quarter's $4.8M loss.

Operating cash flow was −$1.7M. Non-cash charges added back $65K of depreciation and amortization and $263K of share-based compensation. Working capital and other items used $1.4M.

Quarterly history

Biofrontera revenue by quarterBiofrontera revenue by quarter$12.6MQ4 2024$8.6MQ1 2025$9.0MQ2 2025$7.0MQ3 2025$17.1MQ4 2025$10.1MQ1 2026$12.0MQ2 2026
Biofrontera net earnings by quarterBiofrontera net earnings by quarter−$1.4MQ4 2024−$4.2MQ1 2025−$5.3MQ2 2025−$6.6MQ3 2025$5.6MQ4 2025−$4.8MQ1 2026−$604KQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 13, 2026$12.0M+33%-4.4%−$604K−$1.7M
Q1 202610-QMay 14, 2026$10.1M+17%-42.8%−$4.8M−$70K
Q4 202510-KMar 19, 2026$17.1M+36%26.7%$5.6M−$2.4M
Q3 202510-QNov 12, 2025$7.0M-22%-89.8%−$6.6M−$3.8M
Q2 202510-QAug 13, 2025$9.0M+15%-56.2%−$5.3M−$3.0M
Q1 202510-QMay 15, 2025$8.6M+8%-52.9%−$4.2M−$4.1M
Q4 202410-KMar 20, 2025$12.6M+18%-13.6%−$1.4M−$1.0M

Charts

Biofrontera: revenue growth, year over year and quarter over quarterBiofrontera: revenue growth, year over year and quarter over quarterY/YQ/Q+18%Q4 2024+8%-32%Q1 2025+15%+5%Q2 2025-22%-23%Q3 2025+36%+145%Q4 2025+17%-41%Q1 2026+33%+19%Q2 2026
Latest (Q2 2026): Y/Y +33%, Q/Q +19%.
Biofrontera: where the cash came from (+) and went (−), TTM to Q2 2026Biofrontera: where the cash came from (+) and went (−), TTM to Q2 2026Operating cash flow−$7.9MOther investing$3.0MCash drawn (+) / kept (−)$2.6MNot reconciled$2.4MCapital spending−$3K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Biofrontera: profit against cash, quarter by quarterBiofrontera: profit against cash, quarter by quarterNet incomeOperating cash flow−$5.7M−$1.2MQ3 2024−$1.4M−$1.0MQ4 2024−$4.2M−$4.1MQ1 2025−$5.3M−$3.0MQ2 2025−$6.6M−$3.8MQ3 2025$5.6M−$2.4MQ4 2025−$4.8M−$70KQ1 2026−$604K−$1.7MQ2 2026
Latest (Q2 2026): Net income −$604K, Operating cash flow −$1.7M.
Biofrontera: diluted shares by fiscal year (split-adjusted)Biofrontera: diluted shares by fiscal year (split-adjusted)183MFY202070.47BFY20218MFY202212MFY202311MFY202410MFY2025
-94.5% since FY2020: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY2025, 4-for-1 split before FY2024.
Biofrontera in its industry: growth against margin (225 companies, SIC 2834)Biofrontera in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMBFRI (+33%, -4%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Biofrontera

We are a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (“PDT”). The Company’s products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamp series (together, the “RhodoLED Lamps”), are used for the treatment of actinic keratosis (“AK”), a common skin condition characterized by the growth of pre-cancerous lesions (or “AKs”). With our national commercial team, we generate revenue by selling our products directly to dermatology offices and groups.

In its own words, from its 10-K, filed Mar 19, 2026.

Biofrontera against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +33% against the peers' median +10%. Operating margin: -4.4% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
BFRI BiofronteraQ2 2026$12.0M+33%-4.4%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Biofrontera 10-Q on SEC EDGAR · CIK 1858685 · Pharmaceutical Preparations

13F: who owns BFRI and who is buying

Largest holders of BFRI (13F)Largest holders of BFRI (13F)Aigh Capital Management LLC$1.6MRosalind Advisors$1.2MRenaissance Technologies LLC$149KCitadel Advisors LLC$99KJane Street Group, LLC$88KGeode Capital Management, LLC$73KVanguard Capital Management LLC$68KVanguard Group$65KVanguard Fiduciary Trust$58KXTX Topco$49K
Funds' net buying of BFRI by quarter (13F)Funds' net buying of BFRI by quarter (13F)−$12K2024-09$682K2024-12−$264K2025-03$129K2025-06$388K2025-09−$55K2025-12$44K2026-03−$786K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on BFRI

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare BFRI with

中文版：Biofrontera（BFRI）财报

Español · Français